Product Information

SUBVENITE 150 MG TABLET is a generic product labeled by OWP Pharmaceuticals, Inc., priced at $0.0707 per EA under NDC 69102015006. Its NADAC has been published 418 times since Aug 22, 2018.

FDA first approved this application on Jan 27, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the LAMOTRIGINE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

SUBVENITE 150 MG TABLET

LAMOTRIGINE
$0.0707per EA
High Outlier

Strength

150 mg/1

NDC

69102015006

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

LAMOTRIGINE

Approval Type

Generic (ANDA)

FDA Application

ANDA078947

FDA Approved

1/27/2009

TE Code

AB

On Market Since

3/10/2018

Pharmacological Classes

Anti-epileptic Agent
Decreased Central Nervous System Disorganized Electrical Activity
Dihydrofolate Reductase Inhibitors
Mood Stabilizer
Organic Cation Transporter 2 Inhibitors

Price Statistics

The NADAC for SUBVENITE 150 MG TABLET has been published 418 times since Aug 22, 2018, and over the history we have for it it has risen 6.4%. The table below summarizes its recorded NADAC range and movement.

Current price$0.0707 per EA
All-time high$0.0921 (Jun 15, 2022)
All-time low$0.0540 (Nov 20, 2024)
52-week high$0.0728
52-week low$0.0630
Median price$0.0711
Average price$0.0720
Largest weekly change+25.4% (Aug 21, 2024)
Weeks tracked418
Tracking sinceAug 22, 2018

Price History

1W

-2.1%

1M

-2.1%

3M

-1.3%

6M

+9.3%

1Y

+5.5%

3Y

-2.8%

5Y

-22.2%

All

+6.4%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 12% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 12%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of SUBVENITE 150 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for SUBVENITE 150 MG TABLET, manufactured by OWP Pharmaceuticals, Inc., is $0.0707 per EA (NDC 69102015006), effective Aug 19, 2026.

How has the price of SUBVENITE 150 MG TABLET changed over time?

Over the history we have for it, the NADAC for SUBVENITE 150 MG TABLET has risen 6.4%. It has been tracked across 418 weekly CMS publications since Aug 22, 2018.

What are the highest and lowest recorded NADAC prices for SUBVENITE 150 MG TABLET?

Since Aug 22, 2018, the NADAC for SUBVENITE 150 MG TABLET has ranged from a low of $0.0540 (Nov 20, 2024) to a high of $0.0921 (Jun 15, 2022), with a median of $0.0711 per EA.

Are there cheaper alternatives to SUBVENITE 150 MG TABLET?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LAMOTRIGINE 150 MG TABLET, is $0.0625 per EA — about 12% below SUBVENITE 150 MG TABLET.

Who manufactures SUBVENITE 150 MG TABLET?

SUBVENITE 150 MG TABLET (NDC 69102015006) is labeled by OWP Pharmaceuticals, Inc., and CMS classifies it as a generic product.